NYKD: Nykode Therapeutics Presents Comprehensive Preclinical Data, Optimized Manufacturing, and Durable Clinical Immunogenicity for their Individualized Neoantigen Therapy VB10.NEO

	Nykode showcases its Individualized Neoantigen Therapy (INT), VB10.NEO, at the
Neoantigen Summit
	The data underscores the strengths of Nykode's differentiated APC-targeting
and DNA-based INT
	New data demonstrates substantial enhancement of immune response by
co-administration of molecular adjuvants
	Further optimization of the manufacturing process reduces current
turnaround-time to less than 6 weeks with a clear path to further reductions by
additional consolidation under "one roof"
	New post-hoc analysis shows a significant correlation between strong de novo
immune responses and overall survival (OS) in patients with low baseline
immunogenicity
	AI and machine learning support more efficient vaccine design by helping
identify structural elements that enhance antigen secretion and enable selection
of complex antigen designs. 

Oslo, Norway, July 22, 2026 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today presented comprehensive preclinical
and clinical data on VB10.NEO, its individualized neoantigen therapy (INT), at
the Neoantigen Summit in Amsterdam, reinforcing the program as a differentiated
platform ready for strategic partnership.

VB10.NEO is a wholly owned, DNA-based INT built on Nykode's proprietary antigen
presenting cell (APC)-targeting technology and NeoSELECTTM, an AI-driven
neoantigen selection engine.

The preclinical data demonstrates the strength of Nykode's differentiated
APC-targeting, DNA-based vaccine platform, which shows a strong immunogenicity
advantage over non-APC-targeted vaccines.  New data showcases further enhanced
immune responses with co-administration of molecular adjuvants. VB10.NEO
generated robust CD4+ and CD8+ T cell responses across multiple tumor models,
demonstrated stronger immune responses than peptide vaccines, durable tumor
protection, and improved anti-tumor activity in combination with anti-CTLA4 or
anti-PD-L1 antibody checkpoint inhibitors. 

Nykode is dedicated to leverage AI and machine learning to optimize vaccine
design, with new data demonstrating improved antigen secretion and selection of
complex antigen designs. 

"VB10.NEO is a highly differentiated individualized neoantigen therapy,
combining broad, durable immune responses with scalable manufacturing. Together
with our new data pointing to further optimized immune responses and further
reduced manufacturing timelines, we have strengthened our confidence around
VB10.NEO's potential."  said Agnete Fredriksen, CSO and Co-founder of Nykode
Therapeutics. 

Nykode has established a clinically validated end-to-end manufacturing process
for VB10.NEO, achieving 100% manufacturing success across two clinical trials.
Recent improvements have meaningfully reduced manufacturing time, with a current
process of under six weeks from biopsy to release. This positions Nykode as one
of the fastest and most robust INT developers on the market. Future
establishment of an in-house process will create a scalable, time- and
cost-competitive supply chain where Nykode's simpler plasmid DNA manufacturing
process will have an inherent cost-of-goods and needle to needle time advantage
over alternative technologies such as mRNA-LNP.

NeoSELECTTM, Nykode's proprietary AI-powered neoantigen selection algorithm,
demonstrated a significant correlation between highly ranked neoantigens and
immunogenicity in patients. The platform was recently strengthened by a new U.S.
patent extending protection through 2039. 

Across two clinical trials in advanced solid tumors, VB10.NEO was safe and well
tolerated, with no serious vaccine-related adverse events. Vaccine-specific
immune responses were observed in 88-100% of patients, including de novo T cell
responses in 85% of patients, and remained durable for more than one year after
the final dose. 

A new post-hoc analysis indicates that patients with a higher number of
vaccine-induced immune responses showed a trend toward improved overall
survival, while patients with baseline immune response to a higher number of the
selected neoantigens had a significant correlation with improved overall
survival, indicating that Nykode's vaccines target clinically meaningful
neoantigens. Importantly, in patients with baseline immune response to a lower
number of neoantigens, a higher number of de novo vaccine-induced immune
responses was significantly correlated with an overall survival benefit,
indicating the potential of VB10.NEO to target relevant neoantigens and provide
clinical benefit to cancer patients with an insufficient immune response to
these neoantigens.
  
Nykode is actively exploring partnerships to advance VB10.NEO across a broad
range of tumor types.

The poster will be available after the session at the Company's Webpage:
https://nykode.com/research-and-development/scientific-papers-and-presentations/


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy
technology specifically targets antigens to antigen presenting cells (APCs),
which have been shown to induce a broad, strong and long-lasting antigen
specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for
the treatment of HPV16 induced malignancies which demonstrated favorable safety
and efficacy results from its Phase 2 trial for the treatment of late-line r/m
cervical cancer. Abi-suva is currently being further developed in first line
head and neck cancer with the randomized Abili-T trial with interim results
within 2027. VB10.NEO, an individualized cancer neoantigen immunotherapy, has
been investigated in two trials with more than 10 different indications. 

Nykode is also utilizing its APC-targeted technology to create an immune
tolerance platform for the potential use in autoimmune disorders, organ
transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
IR@nykode.com

Contact for Business Development: 
CSO and Co-founder Agnete Fredriksen: BD@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

\
Contact for Business Development: \
CSO and Co-founder Agnete Fredriksen: BD@nykode.com\
\
Nykode Therapeutics ASA\
Oslo Science Park\
Gaustadalléen 21\
N-0349 Oslo\, Norway\